{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:23:42Z","timestamp":1783981422864,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 infection-induced hyper-inflammation links to the acute lung injury and COVID-19 severity. Identifying the primary mediators that initiate the uncontrolled hypercytokinemia is essential for treatments. Mast cells (MCs) are strategically located at the mucosa and beneficially or detrimentally regulate immune inflammations. In this study, we showed that SARS-CoV-2-triggered MC degranulation initiated alveolar epithelial inflammation and lung injury. SARS-CoV-2 challenge induced MC degranulation in ACE-2 humanized mice and rhesus macaques, and a rapid MC degranulation could be recapitulated with Spike-RBD binding to ACE2 in cells; MC degranulation altered various signaling pathways in alveolar epithelial cells, particularly, the induction of pro-inflammatory factors and consequential disruption of tight junctions. Importantly, the administration of clinical MC stabilizers for blocking degranulation dampened SARS-CoV-2-induced production of pro-inflammatory factors and prevented lung injury. These findings uncover a novel mechanism for SARS-CoV-2 initiating lung inflammation, and suggest an off-label use of MC stabilizer as immunomodulators for COVID-19 treatments.<\/jats:p>","DOI":"10.1038\/s41392-021-00849-0","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T02:02:50Z","timestamp":1639706570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury"],"prefix":"10.1038","volume":"6","author":[{"given":"Meng-Li","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-5012","authenticated-orcid":false,"given":"Feng-Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Heng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-5589","authenticated-orcid":false,"given":"Jincun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-0324","authenticated-orcid":false,"given":"Yong-Tang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"849_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","volume":"590","author":"M O\u2019Driscoll","year":"2021","unstructured":"O\u2019Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140\u2013145 (2021).","journal-title":"Nature"},{"key":"849_CR2","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMp2032369","volume":"383","author":"D Rubin","year":"2020","unstructured":"Rubin, D., Chan-Tack, K., Farley, J. & Sherwat, A. FDA approval of remdesivir - a step in the right direction. N. Engl. J. Med 383, 2598\u20132600 (2020).","journal-title":"N. Engl. J. Med"},{"key":"849_CR3","doi-asserted-by":"publisher","first-page":"n2697","DOI":"10.1136\/bmj.n2697","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: UK becomes first country to authorise antiviral molnupiravir. BMJ 375, n2697 (2021).","journal-title":"BMJ"},{"key":"849_CR4","doi-asserted-by":"publisher","first-page":"n2422","DOI":"10.1136\/bmj.n2422","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ 375, n2422 (2021).","journal-title":"BMJ"},{"key":"849_CR5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3892\/etm.2021.10843","volume":"22","author":"G Marfe","year":"2021","unstructured":"Marfe, G., Perna, S. & Shukla, A. K. Effectiveness of COVID-19 vaccines and their challenges (Review). Exp. Ther. Med. 22, 1407 (2021).","journal-title":"Exp. Ther. Med."},{"key":"849_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355\u2013362 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"849_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41577-020-0319-0","volume":"20","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Advancing scientific knowledge in times of pandemics. Nat. Rev. Immunol. 20, 338 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"849_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","volume":"27","author":"Z Zhou","year":"2020","unstructured":"Zhou, Z. et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883\u2013890 e882 (2020).","journal-title":"Cell Host Microbe"},{"key":"849_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R Wolfel","year":"2020","unstructured":"Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"849_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med. 8, 420\u2013422 (2020).","journal-title":"Lancet Respiratory Med."},{"key":"849_CR11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1080\/21505594.2021.1898790","volume":"12","author":"M Jamal","year":"2021","unstructured":"Jamal, M. et al. Immune dysregulation and system pathology in COVID-19. Virulence 12, 918\u2013936 (2021).","journal-title":"Virulence"},{"key":"849_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636\u20131643 (2020).","journal-title":"Nat. Med."},{"key":"849_CR13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.cell.2021.01.053","volume":"184","author":"X Ren","year":"2021","unstructured":"Ren, X. et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184, 1895\u20131913 e1819 (2021).","journal-title":"Cell"},{"key":"849_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036\u20131045 e1039 (2020).","journal-title":"Cell"},{"key":"849_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"849_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijid.2020.04.041","volume":"95","author":"Z Zhu","year":"2020","unstructured":"Zhu, Z. et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J. Infect. Dis. 95, 332\u2013339 (2020).","journal-title":"Int J. Infect. Dis."},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"849_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2355-0","volume":"583","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 583, 437\u2013440 (2020).","journal-title":"Nature"},{"key":"849_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"849_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","volume":"146","author":"T Herold","year":"2020","unstructured":"Herold, T. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 146, 128\u2013136 e124 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"849_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/07853890.2020.1840621","volume":"53","author":"N Broman","year":"2021","unstructured":"Broman, N. et al. IL-6 and other biomarkers as predictors of severity in COVID-19. Ann. Med. 53, 410\u2013412 (2021).","journal-title":"Ann. Med."},{"key":"849_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","volume":"170","author":"JY Chung","year":"2021","unstructured":"Chung, J. Y., Thone, M. N. & Kwon, Y. J. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv. Drug Deliv. Rev. 170, 1\u201325 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"849_CR23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine Storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"849_CR24","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117, 10970\u201310975 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"849_CR25","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","volume":"34","author":"F La Rosee","year":"2020","unstructured":"La Rosee, F. et al. The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia 34, 1805\u20131815 (2020).","journal-title":"Leukemia"},{"key":"849_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RC Group","year":"2021","unstructured":"Group, R. C. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"849_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41565-020-0752-z","volume":"15","author":"T Lammers","year":"2020","unstructured":"Lammers, T. et al. Dexamethasone nanomedicines for COVID-19. Nat. Nanotechnol. 15, 622\u2013624 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"849_CR28","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"Group, W. H. O. R. E. A. f. C.-T. W.","year":"2020","unstructured":"Group, W. H. O. R. E. A. f. C.-T. W. et al. Association between Administration of Systemic Corticosteroids and Mortality among critically Ill patients With COVID-19: a meta-analysis. JAMA 324, 1330\u20131341 (2020).","journal-title":"JAMA"},{"key":"849_CR29","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 383, 2333\u20132344 (2020).","journal-title":"N. Engl. J. Med."},{"key":"849_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama, C. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med 384, 20\u201330 (2021).","journal-title":"N. Engl. J. Med"},{"key":"849_CR31","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","volume":"79","author":"E Della-Torre","year":"2020","unstructured":"Della-Torre, E. et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann. Rheum. Dis. 79, 1277\u20131285 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"849_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","volume":"395","author":"A Remuzzi","year":"2020","unstructured":"Remuzzi, A. & Remuzzi, G. COVID-19 and Italy: what next? Lancet 395, 1225\u20131228 (2020).","journal-title":"Lancet"},{"key":"849_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04574-1","volume":"9","author":"A Singanayagam","year":"2018","unstructured":"Singanayagam, A. et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat. Commun. 9, 2229 (2018).","journal-title":"Nat. Commun."},{"key":"849_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep07176","volume":"4","author":"BJ Thomas","year":"2014","unstructured":"Thomas, B. J., Porritt, R. A., Hertzog, P. J., Bardin, P. G. & Tate, M. D. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci. Rep. 4, 7176 (2014).","journal-title":"Sci. Rep."},{"key":"849_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00110-21","author":"S Deinhardt-Emmer","year":"2021","unstructured":"Deinhardt-Emmer, S. et al. SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00110-21 (2021).","journal-title":"J. Virol."},{"key":"849_CR36","doi-asserted-by":"publisher","first-page":"e21577","DOI":"10.1096\/fj.202100024R","volume":"35","author":"N Degauque","year":"2021","unstructured":"Degauque, N., Haziot, A., Brouard, S. & Mooney, N. Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection. FASEB J. 35, e21577 (2021).","journal-title":"FASEB J."},{"key":"849_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03252-9","volume":"11","author":"P Wang","year":"2020","unstructured":"Wang, P. et al. A cross-talk between epithelium and endothelium mediates human alveolar-capillary injury during SARS-CoV-2 infection. Cell Death Dis. 11, 1042 (2020).","journal-title":"Cell Death Dis."},{"key":"849_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41379-020-0536-x","volume":"33","author":"S Tian","year":"2020","unstructured":"Tian, S. et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod. Pathol. 33, 1007\u20131014 (2020).","journal-title":"Mod. Pathol."},{"key":"849_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med"},{"key":"849_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fimmu.2012.00046","volume":"3","author":"A Carroll-Portillo","year":"2012","unstructured":"Carroll-Portillo, A., Surviladze, Z., Cambi, A., Lidke, D. S. & Wilson, B. S. Mast cell synapses and exosomes: membrane contacts for information exchange. Front Immunol. 3, 46 (2012).","journal-title":"Front Immunol."},{"key":"849_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nri2782","volume":"10","author":"SN Abraham","year":"2010","unstructured":"Abraham, S. N. & St John, A. L. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 10, 440\u2013452 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"849_CR42","doi-asserted-by":"publisher","unstructured":"Marshall, J. S., Portales-Cervantes, L. & Leong, E. Mast cell responses to viruses and pathogen products. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20174241 (2019).","DOI":"10.3390\/ijms20174241"},{"key":"849_CR43","first-page":"101292","volume":"31","author":"AF Ribeiro Dos Santos Miggiolaro","year":"2020","unstructured":"Ribeiro Dos Santos Miggiolaro, A. F. et al. Covid-19 cytokine storm in pulmonary tissue: anatomopathological and immunohistochemical findings. Respir. Med. Case Rep. 31, 101292 (2020).","journal-title":"Respir. Med. Case Rep."},{"key":"849_CR44","doi-asserted-by":"publisher","first-page":"574862","DOI":"10.3389\/fimmu.2020.574862","volume":"11","author":"JDS Motta Junior","year":"2020","unstructured":"Motta Junior, J. D. S. et al. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Front Immunol. 11, 574862 (2020).","journal-title":"Front Immunol."},{"key":"849_CR45","doi-asserted-by":"publisher","first-page":"633680","DOI":"10.3389\/fphar.2021.633680","volume":"12","author":"RW Malone","year":"2021","unstructured":"Malone, R. W. et al. COVID-19: famotidine, histamine, mast cells, and mechanisms. Front Pharm. 12, 633680 (2021).","journal-title":"Front Pharm."},{"key":"849_CR46","doi-asserted-by":"publisher","first-page":"nwaa285","DOI":"10.1093\/nsr\/nwaa285","volume":"8","author":"FL Liu","year":"2021","unstructured":"Liu, F. L. et al. Rapid generation of ACE2 humanized inbred mouse model for COVID-19 with tetraploid complementation. Natl Sci. Rev. 8, nwaa285 (2021).","journal-title":"Natl Sci. Rev"},{"key":"849_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"RD Jiang","year":"2020","unstructured":"Jiang, R. D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358 e58 (2020).","journal-title":"Cell"},{"key":"849_CR48","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1126\/science.abc4730","volume":"369","author":"H Gu","year":"2020","unstructured":"Gu, H. et al. Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy. Science 369, 1603\u20131607 (2020).","journal-title":"Science"},{"key":"849_CR49","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1368-8375(98)00013-X","volume":"34","author":"Y Aalto","year":"1998","unstructured":"Aalto, Y., Forsgren, S., Franzen, L. & Henriksson, R. Is radiation-induced degranulation of mast cells in salivary glands induced by substance P? Oral. Oncol. 34, 332\u2013339 (1998).","journal-title":"Oral. Oncol."},{"key":"849_CR50","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743 e735 (2020).","journal-title":"Cell"},{"key":"849_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.24272\/j.issn.2095-8137.2020.202","volume":"41","author":"TZ Song","year":"2020","unstructured":"Song, T. Z. et al. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zool. Res. 41, 503\u2013516 (2020).","journal-title":"Zool. Res."},{"key":"849_CR52","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1172\/JCI115385","volume":"88","author":"Y Zhang","year":"1991","unstructured":"Zhang, Y., Ramos, B. F. & Jakschik, B. A. Augmentation of reverse arthus reaction by mast cells in mice. J. Clin. Invest. 88, 841\u2013846 (1991).","journal-title":"J. Clin. Invest."},{"key":"849_CR53","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"849_CR54","doi-asserted-by":"publisher","unstructured":"Stefanie Deinhardt-Emmer, S. B., Clio Haring, Liane Giebeler, Andreas Henke. <SARS-CoV-2 Causes Severe Epithelial Inflammation and Barrier.pdf>. J. Virol https:\/\/doi.org\/10.1128\/JVI (2021).","DOI":"10.1128\/JVI"},{"key":"849_CR55","doi-asserted-by":"publisher","first-page":"106239","DOI":"10.1016\/j.rmed.2020.106239","volume":"176","author":"SS Batah","year":"2021","unstructured":"Batah, S. S. & Fabro, A. T. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir. Med. 176, 106239 (2021).","journal-title":"Respir. Med."},{"key":"849_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/vms3.336","volume":"7","author":"S Gamperl","year":"2021","unstructured":"Gamperl, S., Stefanzl, G., Willmann, M., Valent, P. & Hadzijusufovic, E. In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. Vet. Med. Sci. 7, 57\u201368 (2021).","journal-title":"Vet. Med. Sci."},{"key":"849_CR57","doi-asserted-by":"publisher","unstructured":"Xie, C. L. et al. Anti-allergic compounds from the deep-sea-derived actinomycete nesterenkonia flava MCCC 1K00610. Mar Drugs 15, https:\/\/doi.org\/10.3390\/md15030071 (2017).","DOI":"10.3390\/md15030071"},{"key":"849_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1398-9995.2004.00641.x","volume":"60","author":"YH Wang","year":"2005","unstructured":"Wang, Y. H. et al. Desloratadine prevents compound 48\/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 60, 117\u2013124 (2005).","journal-title":"Allergy"},{"key":"849_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2230.2005.01721.x","volume":"30","author":"Q Xia","year":"2005","unstructured":"Xia, Q. et al. The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine. Clin. Exp. Dermatol. 30, 165\u2013170 (2005).","journal-title":"Clin. Exp. Dermatol."},{"key":"849_CR60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1254\/fpj.103.121","volume":"103","author":"I Yakuo","year":"1994","unstructured":"Yakuo, I. et al. [Pharmacological study of ebastine, a novel histamine H1-receptor antagonist]. Nihon Yakurigaku Zasshi 103, 121\u2013135 (1994).","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"849_CR61","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2217\/14622416.10.3.375","volume":"10","author":"NS Palikhe","year":"2009","unstructured":"Palikhe, N. S. et al. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics 10, 375\u2013383 (2009).","journal-title":"Pharmacogenomics"},{"key":"849_CR62","doi-asserted-by":"publisher","unstructured":"Rahman, M. M., Afroz, S., Arthur, S. & Sundaram, U. Mast cell mediated regulation of small intestinal chloride malabsorption in SAMP1\/YitFc mouse model of spontaneous chronic Ileitis. Cells 10, https:\/\/doi.org\/10.3390\/cells10030697 (2021).","DOI":"10.3390\/cells10030697"},{"key":"849_CR63","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/infdis\/jiaa756","volume":"223","author":"E Petito","year":"2021","unstructured":"Petito, E. et al. Association of neutrophil activation, more than platelet activation, with thrombotic complications in coronavirus disease 2019. J. Infect. Dis. 223, 933\u2013944 (2021).","journal-title":"J. Infect. Dis."},{"key":"849_CR64","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.jinf.2020.06.061","volume":"81","author":"T Ueland","year":"2020","unstructured":"Ueland, T. et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J. Infect. 81, e41\u2013e43 (2020).","journal-title":"J. Infect."},{"key":"849_CR65","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1183\/09031936.00032111","volume":"38","author":"A Davey","year":"2011","unstructured":"Davey, A., McAuley, D. F. & O\u2019Kane, C. M. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur. Respir. J. 38, 959\u2013970 (2011).","journal-title":"Eur. Respir. J."},{"key":"849_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1165\/rcmb.2015-0020TR","volume":"53","author":"VJ Craig","year":"2015","unstructured":"Craig, V. J., Zhang, L., Hagood, J. S. & Owen, C. A. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 53, 585\u2013600 (2015).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"849_CR67","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.molcel.2020.11.028","volume":"80","author":"RM Hekman","year":"2020","unstructured":"Hekman, R. M. et al. Actionable cytopathogenic host responses of human alveolar type 2 cells to SARS-CoV-2. Mol. Cell 80, 1104\u20131122 e1109 (2020).","journal-title":"Mol. Cell"},{"key":"849_CR68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41564-020-00841-4","volume":"6","author":"DK Singh","year":"2021","unstructured":"Singh, D. K. et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat. Microbiol. 6, 73\u201386 (2021).","journal-title":"Nat. Microbiol."},{"key":"849_CR69","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116 (2005).","journal-title":"Nature"},{"key":"849_CR70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/cvr\/cvr147","volume":"92","author":"C Company","year":"2011","unstructured":"Company, C. et al. Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo. Cardiovasc Res. 92, 48\u201356 (2011).","journal-title":"Cardiovasc Res."},{"key":"849_CR71","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1172\/JCI128426","volume":"129","author":"AP Rathore","year":"2019","unstructured":"Rathore, A. P. et al. Dengue virus-elicited tryptase induces endothelial permeability and shock. J. Clin. Invest. 129, 4180\u20134193 (2019).","journal-title":"J. Clin. Invest."},{"key":"849_CR72","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","volume":"182","author":"M Bouhaddou","year":"2020","unstructured":"Bouhaddou, M. et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell 182, 685\u2013712 e619 (2020).","journal-title":"Cell"},{"key":"849_CR73","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012 e1019 (2020).","journal-title":"Cell"},{"key":"849_CR74","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41392-021-00734-w","volume":"6","author":"HY Zheng","year":"2021","unstructured":"Zheng, H. Y. et al. Pro-inflammatory microenvironment and systemic accumulation of CXCR3+ cell exacerbate lung pathology of old rhesus macaques infected with SARS-CoV-2. Signal Transduct. Target Ther. 6, 328 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"849_CR75","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"849_CR76","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569\u20131578 (2020).","journal-title":"Lancet"},{"key":"849_CR77","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/07853890.2021.1875500","volume":"53","author":"A Wadaa-Allah","year":"2021","unstructured":"Wadaa-Allah, A. et al. Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. Ann. Med. 53, 318\u2013334 (2021).","journal-title":"Ann. Med."},{"key":"849_CR78","doi-asserted-by":"publisher","unstructured":"Fujii, S. et al. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J. Infect. Chemother. https:\/\/doi.org\/10.1016\/j.jiac.2021.04.013 (2021).","DOI":"10.1016\/j.jiac.2021.04.013"},{"key":"849_CR79","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","volume":"5","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct. Target Ther. 5, 282 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"849_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1038\/s41392-025-02465-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000}}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00849-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:02:11Z","timestamp":1761984131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00849-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1038\/s41392-021-00849-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.24.449680","asserted-by":"object"}]},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"28 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41392-025-02465-8","URL":"https:\/\/doi.org\/10.1038\/s41392-025-02465-8","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"428"}}